[PDF][PDF] Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy
J Clin Oncol, 2012•academia.edu
Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory
Peripheral T-Cell Lymphoma After Prio Page 1 Results From a Pivotal, Open-Label, Phase II
Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior
Systemic Therapy Bertrand Coiffier, Barbara Pro, H. Miles Prince, Francine Foss, Lubomir Sokol,
Matthew Greenwood, Dolores Caballero, Peter Borchmann, Franck Morschhauser, Martin
Wilhelm, Lauren Pinter-Brown, Swaminathan Padmanabhan, Andrei Shustov, Jean Nichols …
Peripheral T-Cell Lymphoma After Prio Page 1 Results From a Pivotal, Open-Label, Phase II
Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior
Systemic Therapy Bertrand Coiffier, Barbara Pro, H. Miles Prince, Francine Foss, Lubomir Sokol,
Matthew Greenwood, Dolores Caballero, Peter Borchmann, Franck Morschhauser, Martin
Wilhelm, Lauren Pinter-Brown, Swaminathan Padmanabhan, Andrei Shustov, Jean Nichols …
Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prio
academia.edu